Several clinical studies support the idea that the efficacy and safety of L-Asp treatment are closely related to the ALL subtype and specific genetic abnormalities, such as high-risk ALL subtypes, including BCR-ABL-positive ALL and T-ALL (Amylon et al., 1999). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.